Decitabine/Cedazuridine is named as an intervention in 3 current clinical trials in our Australia, Spain and Portugal registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is PETHEMA Foundation (1). The most-studied condition is Myelodysplastic Syndromes.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
NCT07507760 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia With Gene Mutations
|
Phase 2 | Recruiting | PETHEMA Foundation | Spain, Portugal |
|
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
NCT05636514 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
|
Phase 1 | Recruiting | Clinical Hub for Interventional Research (CHOIR) | Australia |
|
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
NCT05883956 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic
|
Phase 3 | Active, closed | Otsuka Australia Pharmaceutical Pty Ltd | Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| PETHEMA Foundation | 1 |
| Clinical Hub for Interventional Research (CHOIR) | 1 |
| Otsuka Australia Pharmaceutical Pty Ltd | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Australia | 2 | 1 |
| Clinical trials in Spain | 1 | 1 |
| Clinical trials in Portugal | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Australia, Spain and Portugal registers name Decitabine/Cedazuridine as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Australia, 1 with sites in Spain and 1 with sites in Portugal. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
PETHEMA Foundation (1), Clinical Hub for Interventional Research (CHOIR) (1) and Otsuka Australia Pharmaceutical Pty Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Decitabine/Cedazuridine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Decitabine/Cedazuridine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Decitabine/Cedazuridine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.